Introduction

Ubigene Biosciences (Ubigene) was established by a group of accomplished scientists with extensive experience in the life sciences. The company has grown into a globally oriented biotechnology enterprise, operating more than 3,000 m² of state-of-the-art research facilities. These include an integrated gene editing platform, a comprehensive cell biology platform, and a fully developed portfolio of gene editing products—collectively enabling high-quality, reliable experimental support for modern biological research.

Since its inception, Ubigene has provided gene editing tools and technical services to over 10,000 life science laboratories, pharmaceutical companies, and contract research organizations (CROs) worldwide. Through consistent quality and technical rigor, the company has earned strong recognition and trust across the scientific community.

“Making genome editing easier” has always been the core mission of Ubigene Biosciences. Continuous technological innovation drives the company’s rapid growth, while pragmatism, efficiency, transparency, and integrity form the foundation of our corporate values.

Ubigene's Technology Platforms and R&D Capabilities

1.CRISPR-U™ Gene Editing Platform

Ubigene's proprietary CRISPR-U™ gene editing platform represents a systematic innovation built upon conventional CRISPR/Cas9 methodologies. The platform integrates an intelligent gRNA-design algorithm informed by cellular genomic features, optimized editing strategies tailored for diverse cell lines, and a high-precision single-clone screening workflow. Together, these advancements enable a 10-20-fold improvement in knockout efficiency, effectively overcoming the limitations of low efficiency and labor-intensive screening associated with traditional approaches.

Leveraging the CRISPR-U™platform, Ubigene has successfully generated gene-edited models across more than 300 cell types and has completed over 13,000 gene editing projects. This extensive experience has allowed the company to establish a robust technical foundation and a highly reliable quality control system for stable cell line development. With CRISPR-U™, clients can obtain stable knockout cell lines in as little as four weeks, accompanied by comprehensive and rigorously validated quality reports. By deeply optimizing single-cell clone formation and genotyping workflows, CRISPR-U™ significantly enhances editing success rates, data accuracy, and experimental throughput—delivering high-efficiency, high-reliability gene editing solutions to support both basic research and drug discovery.

2.CRISPR-iScreen™ Platform

The CRISPR-iScreen™ library screening platform is Ubigene's fully integrated, end-to-end system designed for high-throughput target discovery. The platform encompasses the entire workflow—from library generation to data interpretation—and supports CRISPR-KO, CRISPRa, and CRISPRi screening modalities, addressing a wide spectrum of research needs including gene function studies, drug target identification, and pathway analysis. CRISPR-iScreen™ delivers a complete service pipeline covering gRNA library preparation, lentiviral production, cell transduction, in vitro or in vivo screening under selective pressure, and high-throughput sequencing-based readout. With Ubigene's internally optimized competent E. coli strains and standardized Cell Pool preparation processes, the platform achieves >99% library coverage with <10% distribution bias, ensuring stable and reproducible screening performance.

The system supports diverse screening strategies such as compound treatment, longitudinal passaging selection, and flow-cytometry-based enrichment, enabling flexible phenotypic profiling across drug response, proliferation, survival, and phenotypic switching studies. To streamline downstream analysis, the platform is complemented by iScreenAnlys™ CRISPR Library Analysis Platform, Ubigene's visualization-driven data analysis suite. Researchers can obtain publication-ready figures and summary reports without programming, significantly accelerating data processing and facilitating rapid scientific output.

3.Red Cotton CRISPR Gene Editing Designer

The Red Cotton CRISPR Gene Editing Designer is Ubigene's proprietary intelligent and automated design platform, built upon extensive experience accumulated from thousands of gene editing projects and powered by advanced bioinformatics algorithms. By simply inputting the target gene and cell line information, the system can automatically generate multiple gene editing strategies—including knockout, knockin, and point mutation designs.

The platform incorporates a suite of multi-dimensional assessment tools, such as gene risk evaluation, expression-level profiling, and copy-number assessment. These features enable systematic evaluation of experimental complexity, editing feasibility, and potential off-target concerns, providing researchers with a more informed and reliable basis for experimental planning. With highly optimized algorithms, Red Cotton can generate three independent knockout design schemes within one minute, significantly reducing manual selection efforts and accelerating the overall design workflow.

Building upon the Red Cotton system, Ubigene also offers downstream services—including vector construction, viral packaging, and customized gene-edited cell line development—providing an integrated, end-to-end solution from design to final deliverable. This seamless workflow offers researchers a convenient, efficient, and practical path to high-quality gene editing outcomes.

4. iScreenAnlys™ CRISPR Library Analysis Platform

The iScreenAnlys™ CRISPR Library Analysis Platform is Ubigene’s newly developed end-to-end data analysis system designed to deliver a truly “one-click” analysis experience. The platform integrates the MAGeCK statistical workflow with a comprehensive quality-control framework, enabling automated execution of all key steps—from data preprocessing and quality assessment to differential abundance analysis and candidate gene identification. The system generates standardized, publication-ready visualizations and reports, requiring no programming experience from the user.

Researchers simply upload their sequencing data and initiate the analysis; iScreenAnlys™ then performs the entire workflow autonomously. The platform also supports multiple statistical options, customizable parameters, and extensible configuration modes, making it adaptable to a wide range of screening strategies and experimental designs. This flexibility allows even users without a bioinformatics background to efficiently generate accurate and reliable analysis outputs.

With its high level of automation, processing stability, and analytical precision, the iScreenAnlys™ platform empowers researchers to rapidly pinpoint biologically meaningful hits, substantially improving the efficiency and reliability of CRISPR library screening projects.

EZ-editor™ Product Matrix

EZ-editor™ Product Center integrates Ubigene’s 15 years of expertise in gene-editing R&D, offering a comprehensive product ecosystem that spans wet-lab tools, engineered cell models, and data-analysis software. Built around three major product lines, the EZ-editor™ portfolio provides researchers with a complete workflow—from experimental design to result validation. Key product categories include:

Red Cotton OmniCell Bank： A curated collection of 11,000+ cell lines, providing robust and reliable model systems for diverse research scenarios.

CRISPR-iScreen™ Library Products： A broad catalogue consisting of 40+ CRISPR library plasmids, 150+ CRISPR library lentiviruses, and 400+ CRISPR library cell pools, supporting KO, CRISPRa, and CRISPRi screening applications.

EZ-editor™ Gene-Editing Tools： A full suite of ready-to-use lab kits and reagents, including: Mouse Genotyping Kit, Monoclone Genotype Validation Kit, Culture Medium, Red Cotton™ gRNA Plasmid Bank, featuring both standard knockout vectors and lentiviral backbone vectors.

All products in the EZ-editor™ portfolio are built on systematically optimized designs that streamline experimental workflows while enhancing editing efficiency and reproducibility. By leveraging the EZ-editor™ ecosystem, researchers can conduct gene-editing and cell-culture workflows with greater ease and reliability—allowing them to focus more fully on the scientific questions that truly matter.

Ubigene Certifications & Recognitions

Since its founding, Ubigene Biosciences has been widely recognized by leading industry and regulatory bodies for its continuous technological innovation and scientific impact. The company has received multiple certifications and honors that underscore its technical strength and long-term potential in the life sciences sector. Ubigene has strategically developed a strong intellectual property portfolio centered on its core gene-editing technologies. The company holds several invention patents, including proprietary algorithms and automated design systems for point-mutation gene-editing strategies. In parallel, Ubigene has obtained a series of software copyrights covering key platforms such as the Red Cotton Point Mutation Design System, the Intelligent Sequencing Trace Analysis System, the DNA Sequence Diversity Alignment Engine, the Red Cotton CRISPR Gene Editing System, and the EZ-editor™ Gene Risk Evaluation Suite. Together, these patents and software assets form a robust technology and algorithm ecosystem. They not only reinforce Ubigene’s leadership in gene editing and bioinformatics but also establish strong technical barriers and competitive advantages that support the company’s continued growth.

Ubigene’s Comprehensive Service System

Ubigene Biosciences has always adhered to a “customer-centric” service philosophy, establishing a one-stop, end-to-end support system that spans pre-sales, project execution, delivery, and post-sales. This framework ensures reliable and efficient technical support for research clients. During the pre-sales phase, Ubigene provides expert consultation and project feasibility assessment through a dedicated technical team, with a commitment to respond to inquiries within 24 hours. The team evaluates customers’ scientific questions and experimental requirements, offering feasibility analyses, experimental design guidance, and technical route planning to ensure reliability from the outset.

In the project execution phase, each project is assigned a dedicated project manager responsible for progress tracking, communication, and risk assessment, ensuring high-quality, on-time project delivery. During the delivery and post-sales phase, Ubigene provides continuous support, including cell recovery guidance, user training, technical Q&A, and operational advice throughout the experiment. In the rare event of product quality issues (e.g., cell viability below quality control standards), the company follows its post-sales policy to replace or remediate products, ensuring that experimental outcomes remain controlled and reproducible.

Overall, from initial consultation to experimental execution and ongoing support, Ubigene provides clear project timelines, regular progress updates, reliable deliverables, and comprehensive post-sales services, allowing researchers to focus entirely on their scientific work with complete peace of mind.

Why Choose Ubigene Biosciences?

Ubigene Biosciences stands out in the field of gene editing through technological leadership, a comprehensive product portfolio, and a global service network, offering researchers efficient, reliable, and end-to-end solutions.

Technological Advantages:

Leveraging its proprietary CRISPR-U™ platform, Ubigene significantly enhances the efficiency and stability of gene editing, improving the success rates of knockout, knockin, and point-mutation experiments. In addition, the Red Cotton® automated design system and iScreenAnlys™ library analysis platform form a complete AI-driven automation toolchain, enabling seamless integration from experimental design to data analysis, simplifying workflows, and increasing experimental throughput.

Product Advantages:

Ubigene maintains an extensive collection of cell lines and CRISPR libraries. The Red Cotton OmniCell Bank comprises over 11,000 cell lines, including 8,000+ knockout cell lines, and more than 2,000 off-the-shelf stable cell lines (including Cas9/GFP/Luc reporter cell lines) ready for rapid delivery to meet diverse experimental needs. The company’s technological achievements are well-documented, with over 300 peer-reviewed citations, reflecting both the reliability of its research tools and broad recognition from the scientific community.

Service Advantages:

Ubigene Biosciences maintains a global service network spanning over 40 countries and regions and has established long-term collaborations with more than 10,000 academic institutions and enterprises, providing comprehensive, professional technical support and project collaboration. Leveraging its technological, product, and service strengths, Ubigene delivers deep technical expertise, extensive experimental resources, and a wide range of application examples, offering end-to-end support for cutting-edge life science research and applied development projects.

Future Outlook

Looking ahead, Ubigene Biosciences will continue to expand the boundaries of its products, technologies, and services, aiming to provide innovative tools and solutions for life science research and biopharmaceutical development. In terms of product and technology innovation, the company plans to further enrich its KO cell line library, covering additional genes and experimental models, while developing next-generation gene editing and regulatory technologies to meet the growing demands of research and drug discovery.

Regarding application expansion, Ubigene will extend its technologies into cutting-edge models such as drug screening models, immune system models, and organoid systems, including tumor organoid construction and engineered immune cell line development. These efforts aim to provide high-value tools for precision medicine and innovative drug development. On the international front, the company will strengthen overseas collaborations, expand its global market presence, and further enhance the international reach and accessibility of its technical services.

With its continuous R&D innovation and comprehensive end-to-end service system, Ubigene Biosciences is committed to delivering diverse, high-quality products and solutions, empowering researchers to achieve new scientific breakthroughs and advancements in the life sciences and biopharmaceutical sectors.

Contact us to get more information >>>